key: cord-0978603-lddbf7b6 authors: Baldassarri, M.; Picchiotti, N.; Fava, F.; Fallerini, C.; Benetti, E.; Daga, S.; Valentino, F.; Doddato, G.; Furini, S.; Giliberti, A.; Tita, R.; Amitrano, S.; Bruttini, M.; Croci, S.; Meloni, I.; Pinto, A. M.; Gabbi, C.; Sciarra, F.; Venneri, M. A.; Gori, M.; Sanarico, M.; Crawley, F. P.; Pagotto, U.; Fanelli, F.; Mezzullo, M.; Dominguez-Garrido, E.; Planas-Serra, L.; Schluter, A.; Colobran, R.; Soler-Palacin, P.; Lapunzina, P.; Tenorio, J.; Spanish Covid HGE,; Pujol, A.; Castagna, M. G.; Marcelli, M.; Isidori, A. M.; GEN-COVID Multicenter Study,; Renieri, A.; Frullanti, E.; Mari, F. title: Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in males. date: 2020-11-05 journal: nan DOI: 10.1101/2020.11.04.20225680 sha: ec2710c21a72b069cd4838d137097ddde2bc4586 doc_id: 978603 cord_uid: lddbf7b6 Background COVID-19 presentation ranges from asymptomatic to fatal. The variability in severity may be due in part to impaired Interferon type I response due to specific mutations in the host genome or to autoantibodies, explaining about 15% of the cases when combined. Exploring the host genome is thus warranted to further elucidate disease variability. Methods We developed a synthetic approach to genetic data representation using machine learning methods to investigate complementary genetic variability in COVID-19 infected patients that may explain disease severity, due to poly-amino acids repeat polymorphisms. Using host whole-exome sequencing data, we compared extreme phenotypic presentations (338 severe versus 300 asymptomatic cases) of the entire (men and women) Italian GEN-COVID cohort of 1178 subjects infected with SARS-CoV-2. We then applied the LASSO Logistic Regression model on Boolean gene-based representation of the poly-amino acids variability. Findings Shorter polyQ alleles ([≤]22) in the androgen receptor (AR) conferred protection against a more severe outcome in COVID-19 infection. In the subgroup of males with age <60 years, testosterone was higher in subjects with AR long-polyQ ([≥]23), possibly indicating receptor resistance (p=0.004 Mann-Whitney U test). Inappropriately low testosterone levels for the long-polyQ alleles predicted the need for intensive care in COVID-19 infected men. In agreement with the known anti-inflammatory action of testosterone, patients with long-polyQ ([≥]23) and age>60 years had increased levels of C Reactive Protein (p=0.018). Interpretation Our results may contribute to design reliable clinical and public health measures and provide a rationale to test testosterone treatment as adjuvant therapy in symptomatic COVID-19 men expressing AR polyQ longer than 23 repeats. Funding MIUR project -Dipartimenti di Eccellenza 2018-2020- to Department of Medical Biotechnologies University of Siena, Italy (Italian D.L. n.18 March 17, 2020). Private donors for COVID research and charity funds from Intesa San Paolo. In a cohort of 1178 men and women with COVID-19, we used a supervised machine learning approach on a synthetic representation of the uncovered variability of the human genome due to poly-amino acid repeats. Comparing the genotype of patients with extreme manifestations (severe vs. asymptomatic), we found that the poly-glutamine repeat of the androgen receptor (AR) gene is relevant for COVID-19 disease and defective AR signaling identifies an association between male sex, testosterone exposure, and COVID-19 outcome. Failure of the endocrine feedback to overcome AR signaling defect by increasing testosterone levels during the infection leads to the fact that polyQ becomes dominant to T levels for the clinical outcome. We identify the first genetic polymorphism predisposing some men to develop a more severe disease irrespectively of age. Based on this, we suggest that sizing the AR poly- Background COVID-19 presentation ranges from asymptomatic to fatal. The variability in severity may be due in part to impaired Interferon type I response due to specific mutations in the host genome or to autoantibodies, explaining about 15% of the cases when combined. Exploring the host genome is thus warranted to further elucidate disease variability. Methods We developed a synthetic approach to genetic data representation using machine learning methods to investigate complementary genetic variability in COVID-19 infected patients that may explain disease severity, due to poly-amino acids repeat polymorphisms. Using host whole-exome sequencing data, we compared extreme phenotypic presentations (338 severe versus 300 asymptomatic cases) of the entire (men and women) Italian GEN-COVID cohort of 1178 subjects infected with SARS-CoV-2. We then applied the LASSO Logistic Regression model on Boolean gene-based representation of the poly-amino acids variability. Findings Shorter polyQ alleles (≤22) in the androgen receptor (AR) conferred protection against a more severe outcome in COVID-19 infection. In the subgroup of males with age <60 years, testosterone was higher in subjects with AR long-polyQ (≥23), possibly indicating receptor resistance (p=0.004 Mann-Whitney U test). Inappropriately low testosterone levels for the long-polyQ alleles predicted the need for intensive care in COVID-19 infected men. In agreement with the known antiinflammatory action of testosterone, patients with long-polyQ (≥23) and age>60 years had This study was based on a preliminary descriptive analysis of a cohort of 35 hospitalized COVID-19 patients that was used to pinpoint a combined model of rare and common host genetic variants. 1 After this initial study, we extended the cohort to more than 1,000 Italian SARS-CoV-2 PCR-positive subjects. 2 Among them, 25% were asymptomatic, 25% were very severe, and the remaining presented with different levels of respiratory failure and multi-organ involvement. 2 Alongside the mode of transmission, viral load, comorbidities, and demographic factors (such as age and sex), the host genetic background appears to play an important role in COVID-19 severity and progression. 3 Data from classical methods of analysis, such as Genome-Wide Association Study (GWAS) or burden gene test on whole-exome sequencing (WES) data, have pinpointed a limited number of genetic factors that do not entirely explain how the host's genetic background contributes to COVID-19 severity 4 . Two groups have recently identified rare variants in the interferon type I pathway that are responsible for inborn errors of immunity in a small percentage of patients and autoantibodies against type I interferon genes in up to 10% of with severe COVID-19 5,6,7 . We hypothesized that most patients might instead have a more complex genetic background consisting of mutations arising in common susceptibility genes where additional private, rare, or low-frequency mutations provide the virus with the most favorable environment for replication, spread, and organ damage. Thus, we have considered the possibility that poly-amino acids repeat polymorphisms may contribute to COVID-19 severity. Our hypothesis was tested using a method of analysis based on a synthetic approach to genetic data representation. Specifically, we considered that polymorphisms in the polyQ tract of the Androgen Receptor (AR) may protect against the development of severe COVID-19. AR contains in its N-terminus domain a polymorphic polyQ tract, ranging between 9 and 36 repeated CAG units in the normal population 8 . In vitro and in vivo studies have demonstrated that the transactivation potential of AR is inversely correlated to repeat length and Q-tract length can significantly influence androgen-dependent physiological processes 8-11 . Several lines of evidence lead to the concept that androgens are relevant to both SARS-CoV-2 infection and COVID-19 disease presentation; however, they seem to have a Janus bifacial way of action 12, 13 . On one side, androgens promote the transcription of the TMPRSS2 gene that encodes a serine protease known to prime the spike (S) protein of coronaviruses, facilitating viral entry into the cells 14 . On the other hand, hypogonadism and not hypergonadism is known to correlate with severe COVID-19 15 and other chronic conditions, partly due to the loss of attenuation of the inflammatory immune response by testosterone [16] [17] [18] . Functional hypogonadism is also very common in male obesity and diabetes mellitus, two recognized factors of poorer prognosis in COVID-19 patients. The synthetic supervised genetic approach reported here contributes to disentangling this complex androgen-COVID-19 relationship. It may also have significant implications for further development of precision medicine in COVID-19 and identifies the use of androgens as a potential way to shape disease outcome as earlier proposed for glucocorticoids 19 , and subsequently demonstrated in a clinical trial 20 . In order to test the role of common poly-amino acid repeat polymorphisms in determining COVID-19 clinical severity, we performed a nested case-control study (NCC), selecting the extreme phenotypic ends of our entire GENCOVID cohort ( Table 1) . ( Figure 1 ). Among 18,439 annotated genes we selected those with amino acid repeats, namely 43 genes, and represented them as a boolean. Logistic regression with LASSO regularization analysis identified AR as the only protective gene (Figure 1, panel A) . As expected, the grid search curve of the cross-validation score (Figure 1, panel C) shows a maximum for an intermediate value of the L1 regularization parameters, and the chosen parameter is 6.31. With this calibration setting, the 10-fold cross-validation provides good performances in terms of accuracy (77%), precision (81%), sensitivity (77%), and specificity (78%) as shown in Figure 1 , panel D. The confusion matrix is reported in In order to validate the results on AR obtained by LASSO logistic regression, we seized the male subset (351 subjects) using the gold standard technique that uses a fluorescent PCR reaction followed by the use of GeneScan Analysis software ® (Applied Biosystems) for sizing the number of triplets 21 . Based on the AR polyQ length, male patients were subdivided into two categories, those having a number of PolyQ repeats less than or equal to 22 repeats, and those having a number of PolyQ repeats greater than or equal to 23 repeats, being 23 repeats the reference sequence on genome browsers. We found that PolyQ repeats below 22 are enriched in the asymptomatic cohort of males. The difference was statistically significant in the group of males younger than 60 years of age in which genetic factors are expected to have a major impact (p-value 0,024) ( All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint We then seized the polyQ repeat in an independent cohort of 158 males from Spain, with age < 60 years and without known comorbidities (117 cases and 41 controls). The association with shorter repeats (≤ 22) and protection was confirmed (p-value 0,014139 by χ 2 test) ( Table 3) . To functionally link the length of the PolyQ repeats to AR functionality, we measured total testosterone (TT) in 183 men using LCMS/MS (Supplementary Table S1 ). TT was higher in patients carrying Hormonal status of the entire male set sized for polyQ according to the age group revealed lower TT and calculated free T levels and higher SHBG levels with increasing age (Supplementary Table S3 ). To evaluate whether the AR receptor reduced activity resulted in signs and symptoms of hypogonadism, subjects were interviewed, post-infection, using a modified version of 2%), anemia (11% vs 2%) and severe erectile dysfunction (22% vs. 9%) were more frequently reported in subjects with ≥ 25 repeats, but not osteopenia/osteoporosis (6% vs 7%). These results indicate a trend toward clinical hypogonadism for those with longer repeats. Conversely, in the entire male dataset, 6 cases of prostate cancer were found All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint annotated in the past-medical history, all in the ≤ 22 glutamines group, suggesting an increased prostate sensitivity to androgens. No difference was found in the prevalence of BPH or 5-alfa-reductase inhibitors use. As the reduced signal transduction of AR might be compensated by higher testosterone levels, as shown in Fig 2a, we tested whether the feedback was sufficient to overcome polyQ repeats. A binomial logistic regression was performed to ascertain the interaction between age, testosterone levels and polyglutamine receptor length on the likelihood that subjects require intensive care during COVID infections. The logistic regression model was highly significant (χ 2 (3) = 18,881, p<0.0001), with the model explaining 7.5% (Nagelkerke /R2) of the variance in COVID19 outcome (Supplementary Table S4 ). A significant testosterone by polyglutamine length interaction was found (p=0.018), suggesting impaired feedback as predictor of the worst outcome, namely intubation or CPAP/BiPAP versus hospitalization not requiring respiratory assistance. To provide a graphical representation, we plotted the ratio between TT serum concentrations and polyQ number vs. clinical outcome (Fig. 2b) . Results show a decreased mean ratio, a sign of an inappropriate rise of TT for increasing polyglutamine repeats, was associated with a worse outcome (p=0.00038). Finally, we tested the relationship between the AR polyQ repeat size and 5 laboratory markers of immunity/inflammation, including CRP, Fibrinogen, IL6, CD4 and NK count. We found that older (≥60) males with AR polyQ tract ≥ 23 have a higher (55.92 versus 48.21 mg/dl) mean value of CRP (p=0.018) and lower mean value of Fibrinogen and a trend of higher IL6 ( Table 4) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint We employed machine learning methodologies to identify a set of genes involved in the severity of COVID-19. In the presence of very high dimensionality, as for instance in a WES study, it is crucial to select the most predictive genes representing patterns of variation (mutations or variants) in subjects with different classes of response (i.e., disease state: from asymptomatic to severe cases). This problem is even more complex in diseases where multiple genes are involved in determining the severity and clinical variability of the pathology. Here, we wanted to represent poly-amino acids repeat polymorphisms that are typically missed in classical GWAS analysis, which concentrates on bi-allelic polymorphisms. We used a machine learning approach and logistic regression with a LASSO regularization to test if using such a simplified representation could lead to a reliable prediction of extreme clinical outcomes (asymptomatic versus severely affected). This approach enabled us to predict such clinical outcomes with 77% sensitivity. AR contains a highly variable polyglutamine repeat (poly-Q) located in the Nterminal domain of the protein, spanning from 9 to 36 glutamine residues in the normal population 5 . AR polyQ length correlates with receptor functionality, with shorter polymorphic glutamine repeats typically associated with higher and longer PolyQ tracts with lower receptor activity. 5 AR is expressed in both males and females, but the bioavailability of its ligands testosterone (T) and dihydrotestosterone (DHT) differs significantly, being much higher in males. As previous studies linked male hypogonadism to a poorer outcome we decided to focus on male patients and demonstrated that shorter polymorphic glutamine repeats (<22) confer protection against life-threatening COVID-19 in a subpopulation of individuals with age <60 years. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint We also confirmed the functional association between polyQ size and receptor activity. Specifically, we showed that longer polyQ size (≥23) is associated with higher serum T levels, suggestive of impaired negative feedback (p=0.0046 at Mann-Whitney U test) at the level of the hypothalamus and pituitary gland, therefore confirming the association between functional hypogonadism and severe COVID-19 infection. As T is known to have an immunomodulatory activity attenuating inflammatory immune responses, 23-27 we hypothesized that a long PolyQ repeat would lead to a proinflammatory status heralded by increased proinflammatory markers 18,28 by conferring decreased AR transcriptional activity. Conversely, men with a more active receptor (short PolyQ tract) would be protected because they can tame the inflammatory response and increase survival regardless of serum T levels. We found that -CRP-, one of the main inflammatory markers, was higher in subjects with a long AR PolyQ tract. This observation not only is in line with the known anti-inflammatory function of testosterone, but also reinforces the functional importance of the AR PolyQ tract and its association with COVID-19 clinical outcome. Furthermore, this observation suggests that CRP is hierarchically more indicative than serum T level, which can be inappropriately normal and mask a functional hypogonadism in men with a long PolyQ repeat. The allele distribution of the PolyQ repeat length varies among different populations, with the shortest in Africans, medium in Caucasians, and longest in Asians 29 . Interestingly, WHO data on mortality rates during the first pandemic wave indicated a higher fatality rate in China and Italy (https://covid19.who.int/) 30 with respect to African. Hence, AR polyQ length variability could represent an explanation for the observed differences in death rate. Moreover, Africans seem to be more prone to infection 31 . This observation could be due to a more active AR receptor, leading to a higher expression of TMPRSS2, a protease essential for SARS-CoV-2 spread 14 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint Different studies have shown an association between hypogonadism and severe COVID-19 15 and other chronic obstructive pulmonary diseases 16, 17 . Our results are in line with these initial observations and contribute to explain a possible mechanism leading to these associations. The present study brings the observations to the upper level, revealing that is the overall androgenic effect -resulting from the interaction of polyQ polymorphism and circulating testosterone levels-to predict the need for intensive care. In infected men, we observed impaired feedback no longer sufficient to compensate for the reduced AR transcriptional activity, leading to the fact that polyQ becomes dominant to T levels. The latter helps to solve some inconsistencies, including the early reports of a slightly better outcome in prostate cancer patients -who tend to have lower polyQ, as in our cohortwhen compared to other cancers. An improvement in peak oxygen saturation in men receiving testosterone replacement therapy has been demonstrated in a randomized controlled trial 32 and could be one of the mechanisms responsible for the observed protective effect of AR's with shorter polyQ tract in COVID-19 patients. Thus, our study has important implications and suggests that androgen therapy could be tested as an adjuvant treatment in COVID-19infected men with functional hypogonadism. Based on the evidence discussed in this paper, a proper randomized controlled trial (RCT) is warranted in COVID-19 male patients with signs of hypoandrogenism and longer AR polyQ tract to test the safety and efficacy of AR agonists, like testosterone, in improving outcome. A simple genetic test measuring the AR receptor PolyQ repeat in male patients could then be introduced to screen individuals more likely to benefit from testosterone therapy. Variants of another X-linked gene, TLR7, have been associated with severe COVID-19 outcomes in young men 6 . In the 2 reported families, the rare TLR7 mutations segregated as a highly penetrant monogenic X-linked recessive trait. While variants in TLR7 gene are expected to account for a small number of severely affected cases, our All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint findings involve a much larger number of subjects, as although the OR is relatively small, long polyQ alleles are relatively common (27%) 33 . Overall, X-linked genetic variants keep coming up as important for defining severe COVID-19 cases in males. In conclusion, we present a method that can predict if subjects infected by SARS-CoV-2 are at risk for life-threatening complications. This approach has 77% accuracy, 81% precision, 77% sensitivity, and 78% specificity. Furthermore, we present evidence suggesting that a more active AR has the potential to confer protection against COVID-19 severity. If confirmed, these observations should be followed by properly conducted clinical trials studying if testosterone helps decrease morbidity and mortality in patients affected by the most severe forms of the disease. Finally, as shown by regression analysis, ORs ranges between 1.26 and 1.45, therefore the risk of carrying a longer AR is much smaller than other already known strong predictors such as age and sex, but still is highly significant, relatively common, and among the very few known genetic predictors of COVID19 outcome. We performed a nested case-control study (NCC). Cases and controls were drawn from the Italian GENCOVID 2 cohort of 1178 subjects infected with SARS-CoV-2 diagnosed either by RT-PCR on nasopharyngeal swab, or by serology test. 2 Demographic characteristics of patients enrolled in the cohort are summarized in Table 1 according to their clinical status. In particular, the cohort was subdivided into 5 groups, based on the type of the respiratory and medical support that was given to the patients: i. endotracheal intubation; ii, CPAP-biPAP ventilation; iii. oxygen administration; iv. hospitalization without respiratory support; v. no hospitalization either because asymptomatic or with minor symptoms of COVID-19 (mild fever, cough, sore throat, etc.). Subjects of the cohort All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint were recruited by Italian hospitals and primary care clinics participating in the GENCOVID Multicenter study previously described 2 . In the current NCC study, cases were selected according to the following inclusion criteria: i. CPAP/biPAP ventilation (230 subjects); ii. endotracheal intubation (108 subjects). As controls, 300 subjects were selected using the sole criterion of not requiring hospitalization. Cases and controls show the extreme phenotypic presentations of the GENCOVID cohort. Exclusion criteria for both cases and controls were i. SARS-CoV-2 infection not confirmed by PCR; ii. not-caucasian ethnicity. Demographic characteristics of the subjects in the NCC study are summarized in Table 1 . To establish allele sizes of the polymorphic triplet in the AR locus, we used the HUMARA assay with minor modifications 21 . Specifically, we performed a fluorescent PCR followed by capillary electrophoresis on an ABI3130 sequencer. Allele size was established using the Genescan Analysis software. In this paper, one of several synthetic approaches to genetic data variability representation is used: poly-amino acids repeat polymorphisms (Benetti et al., Topological Data Analysis on boolean representation of genome variability as a method for discovering the genetic bases of complex disorders. Paper in preparation). Reads were mapped to the hg19 reference genome by the Burrow-Wheeler aligner BWA. Variants calling was performed according to the GATK4 best practice guidelines. Namely, duplicates were first removed by MarkDuplicates, and base qualities were recalibrated using BaseRecalibration and ApplyBQSR. HaplotypeCaller was used to calculate Genomic VCF files for each sample, which were then used for multi-sample calling by GenomicDBImport and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint GenotypeGVCF. In order to improve the specificity-sensitivity balance, variants quality scores were calculated by VariantRecalibrator and ApplyVQSR, and only variants with estimated truth sensitivity above 99.9% were retained. Variants were annotated by ANNOVAR. WES data were represented in a binary mode on a gene-by-gene basis. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint gender, comorbidity (1 if there is at least one comorbidity) and the age, the latter as a continuous variable normalized between 0 and 1. Performances of the model were evaluated using the cross-validation confusion matrix as well as by computing precision, sensitivity, specificity, and the Receiver Operating Characteristic (ROC) curve. Blood samples were collected after an overnight fast, immediately centrifuged at 4 °C and stored at -20 °C until assayed. Blood samples were collected after an overnight fast, immediately centrifuged at 4 °C and stored at -20 °C until assayed. Serum total testosterone was measured using the Access testosterone assay (Beckman Coulter Inc., Fullerton, CA, USA) with a minimum detection limit of 0.35 nmol/L. Reference range for this assay was 6.07-27.1 nmol/L. Thawed plasma underwent 15 min incubation at 56°C for All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint virus inactivation. Afterward, plasma total testosterone was measured by liquid chromatography -tandem mass spectrometry (LC-MS/MS) according to a previously validated method provided with reference values between 9.8 -28.4 nmol/L 36 . In the present study, measurement was performed in 100 µl plasma, with sensitivity limit being 0.270 nmol/L, imprecision ranging 9.8 to 0.7% and accuracy 90.6 to 101.5% at concentration levels between 1.12 and 39.2 nmol/L. A stability test under viral inactivation conditions was performed in 6 samples, revealing a testosterone mean (min-max) % loss of 9.7% (4.6-16.7%). SHBG levels were measured in plasma samples using Quantikine ELISA Kit (DSHBG0B, R&D Systems, Minneapolis, MN, USA) according to the manufacturers' instructions. Serum LH was measured using "Access LH assay " a chemiluminescent, two-step enzyme immunoassay (Beckman Coulter Inc., Fullerton, CA, USA). Sensitivity for the LH determination is 0.2 mIU/mL. Reference range in adult males for this assay is 1.2-8.6 mIU/mL Since serum and plasma Testosterone values were not normally distributed, the statistical analyses were performed using non-parametric tests. In particular, we used the Mann-Whitney U test to compare testosterone levels in males with AR long-polyQ (≥23) versus males with short polyQ (≤22). Logistic regression analysis was performed to ascertain the interaction between age, testosterone, and the number of polyglutamine repetitions and COVID19 outcomes. Box-Tidwell procedure was used to assess linearity and the Hosmer and Lemeshow to assess goodness of fit test. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; This histogram of the LASSO logistic regression weights represents the importance of each feature for the classification task (Figure 1) (Panel A) . The positive weights reflect a susceptible behaviour of the features to the target COVID-19 disease, whereas the negative weights a protective action. The calculated odd ratio of AR short repeats (≤22) is 0,79 i.e. protective. Therefore, the odd ratio of long repeats (≥23) is 1/0,79= 1,27 i.e. severity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint 14 14 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.04.20225680 doi: medRxiv preprint Clinical and molecular characterization of COVID-19 hospitalized patients Influence of CAG Repeat Polymorphism on the Targets of Testosterone Action A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted The interface between innate and adaptive immunity Innate immune recognition Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice Innate immunity Androgen modulation of proinflammatory and anti-inflammatory cytokines during preadipocyte differentiation Ethnic variation in allele distribution of the androgen receptor (AR) (CAG)n repeat 29) Department of Specialized and Internal Medicine, Pneumology Unit and UTIP, San Donato Hospital, Arezzo, Italy 30) Department of Emergency, Anesthesia Unit, Misericordia Hospital 41) Department of Medical and Surgical Sciences for Children and Adults 45) Infectious Diseases Clinic, Department of Medicine 2, Azienda Ospedaliera di Perugia and University of Perugia Italy 51) Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital 54) Department of Molecular Medicine and Medical Biotechnology 59) Department of Medical Sciences, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital 62) Infectious Diseases Clinic, Policlinico San Martino Hospital, IRCCS for Cancer Research Genova, Italy 63) Microbiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Department of Respiratory Diseases This study is part of the GEN-COVID Multicenter Study, The authors declare no competing interests.